Abstracts tagged "axial spondyloarthritis and rheumatoid arthritis (RA)"

Abstract Number: 31 • 2016 ACR/ARHP Annual Meeting
Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments)
Charlotte Jacquemin¹, Herve Servy², Anna Molto³, Jeremie Sellam⁴, Violaine Foltz¹, Frédérique Gandjbakhch¹, Christophe Hudry³, Stéphane Mitrovic¹, Bruno Fautrel¹ and Laure Gossec¹, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Sanoia, La Ciotat, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Rheumatology, Saint-Antoine Hospital, Paris, France
Background/Purpose: The evolution of RA and axSpA is characterized by alternated periods of flares and remission. This fluctuating disease activity can be self-assessed by a…
Abstract Number: 9 • 2015 ACR/ARHP Annual Meeting
Serum Visfatin Levels in Patients with Axial Spondyloarthitis and Early Rheumatoid Arthritis: Relation to Inflammation and Bone Changes
Hana Hulejova¹, Klára Prajzlerová², Olga Krystufkova², Krystýna Grobelná², Maria Filkova², Herman F Mann³, Karel Pavelka⁴, Jiri Vencovsky³ and Ladislav Senolt⁵, ¹Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Visfatin may represent a novel biomarker of disease severity. Serum visfatin levels are elevated in patients with early rheumatoid arthritis (ERA) and axial spondyloarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].